CDK4 and neoplasm: PEG10-positive group showed a trend toward shorter CDK4/6 inhibitor PFS than PEG10-negative group (Fig. 6G; p = 0.144), indicating that PEG10 protein level in the tumor sample may serve as a novel biomarker to predict palbociclib efficacy.